Tirzepatide
FDA APPROVED · RXGIP / GLP-1 dual agonist
Also known as: Mounjaro, Zepbound
FDA approved and prescription only. Sold as Mounjaro (type 2 diabetes) and Zepbound (weight management).
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 279 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Cited references provided
A read on the weight of evidence and regulatory standing behind this compound. It is not a safety score, not a purity or quality rating, and not medical advice. It is not a claim that this compound treats, cures, or prevents any condition, and not an endorsement or a recommendation to buy or use it. A low score means the evidence is thin — not that a product is unsafe; a high score means the evidence is strong — not that anyone should take it. PLOBT is independent and takes no money from any vendor; no company can pay to change this score.
Proven in large human trials: about 20% or more average weight loss at higher doses, and greater weight loss than semaglutide in head-to-head diabetes data. Strongly evidenced.
What it is
Activates two gut-hormone receptors (GIP and GLP-1) to improve insulin response, slow gastric emptying, and reduce appetite.
What the research says
The SURMOUNT trials showed roughly 20% or more average body-weight reduction at higher doses.
Approved on the SURPASS trial program; outperformed semaglutide in head-to-head diabetes data.
Published literature
Live from Europe PMC. Peer-reviewed papers discussing Tirzepatide in their title or abstract, most-cited first. This is how much has been published — not how much is proven in humans. It counts landmark trials, animal studies and reviews alike.
Tirzepatide Once Weekly for the Treatment of Obesity.
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Registered human trials
Live from ClinicalTrials.gov, the US NIH registry of human studies, refreshed daily. Counts studies where Tirzepatide is the intervention being tested.
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease
Phase and status counts reflect the 100 most recent studies; the registered total above is exact.
FDA recalls & enforcement
No FDA recalls are on record for Tirzepatide.
Source: openFDA drug enforcement.
What people log it for
Descriptive, based on what users track. Not an endorsement or a suggested use.
Risks & unknowns
- GI side effects similar to other GLP-1 drugs.
- Muscle loss risk without protein and training.
- Counterfeit and illegal research versions are common.
- Prescription medicine: not for unsupervised use.
Doses reported in studies & protocols
Approved schedules escalate gradually under a prescriber. This is not a recommendation.
Purity reality
Like semaglutide, a heavy counterfeit target outside the pharmacy channel.
None yet. PLOBT does not publish invented purity numbers. Real third-party COA data, mapped to vendor and batch, is in development — and it is the one thing we refuse to fake.
Sources
We cite peer-reviewed journals, PubMed/PMC, FDA and university sources, not vendor marketing.